Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Septal Occluder Prevents Recurrent Ischemic Stroke

By HospiMedica International staff writers
Posted on 11 Apr 2018
An innovative occlusion device facilitates permanent closure of atrial septal defects (ASD) and patent foramen ovale (PFO), including challenging defects.

The Gore Medical Products (Gore; Flagstaff, AZ, USA) Cardioform Septal Occluder is a transcatheter-delivered device comprised of two independent conformable discs that span and cover the heart's anatomy to close defects. More...
Each disc consists of a platinum-filled nitinol wire frame covered with a thin expanded polytetrafluoroethylene (ePTFE) membrane coated with a hydrophilic surface treatment (facilitating echocardiographic imaging). When fully deployed, the Occluder assumes a double-disc configuration to prevent shunting of blood through the defect.

The delivery system consists of a 75 cm working length 10 Fr catheter that is coupled to a handle that facilitates loading, deployment, and locking of the Occluder; the handle also allows repositioning and retrieval, if necessary. The Occluder is available in diameters of 15, 20, 25, and 30 mm, and can be used to close defects of up to 17 mm. Once in position, the Occluder provides optimal apposition to the surrounding anatomy for immediate closure, together with rapid endothelialization and lasting long-term performance.

“The soft and conformable design of Gore's device is ideal for providing long-term repair of PFOs of any shunt size,” said John Rhodes, MD, of the Medical University of South Carolina (MUSC; Charleston, USA). “I am pleased that a device I have grown to trust for ASD closure is now FDA approved for PFO closure as well. The clear reduction in recurrent ischemic stroke provided by PFO closure far outweighs the low risk of serious adverse events.”

When the chambers of a human heart begin to develop, a tunnel is formed between the right and left atria of the heart in order to allow blood to flow directly from the venous to the arterial circulation, circumventing the non-functioning fetal lungs. Following birth, a pressure differential between the right and left atria forms to allow blood flow to the fully functioning lungs, and the tunnel eventually closes completely. When this does not occur, a PFO is formed, allowing blood clots and deoxygenated blood to cross over to the arterial side.

Related Links:
Gore Medical Products


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
MRI System
nanoScan MRI 3T/7T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The 3D-printed microneedle patch boosts live-virus vaccine delivery (Photo courtesy of IIS/University of Tokyo)

3D-Printed Delivery System Enhances Vaccine Delivery Via Microneedle Array Patch

The COVID-19 pandemic underscored the need for efficient, durable, and widely accessible vaccines. Conventional vaccination requires trained personnel and cold-chain logistics, which can slow mass immunization... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.